Company news

Silexion Therapeutics Corp news in 2025

Silexion Therapeutics Corp's news releases, calls and decks from 2025, newest first.

View company

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer

December 16, 2025

Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer

December 2, 2025

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

November 26, 2025

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer

November 25, 2025

Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

November 12, 2025

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

September 30, 2025

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

September 25, 2025

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

September 11, 2025

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

September 11, 2025

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

September 4, 2025

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

September 2, 2025

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 12, 2025

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

July 31, 2025

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

July 31, 2025

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

July 16, 2025

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

July 9, 2025

Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers

May 29, 2025

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung Cancer

May 21, 2025

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

April 23, 2025

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

March 28, 2025

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

March 21, 2025

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

March 18, 2025

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

March 5, 2025

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

February 25, 2025

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

January 28, 2025

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

January 27, 2025

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

January 14, 2025

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

January 14, 2025

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

January 12, 2025

Decks in 2025